logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
after Q4 2019
Zosano Pharma Corporation
NDA filing for M207
Migraine
after Q4 2019
Oragenics Inc.
Top-line results from phase II clinical trial of AG013
Oral Mucositis
after Q4 2019
Avenue Therapeutics, Inc.
Filing of NDA for intravenous Tramadol
Bunionectomy surgery
after Q4 2019
Caladrius Biosciences, Inc.
Results from phase I/II proof of concept study of CLBS14
Coronary microvascular dysfunction
after Q4 2019
CTI BioPharma Corp.
Full top-line data from ongoing phase II study of Pacritinib (PAC203)
Myelofibrosis
after Q4 2019
Neurocrine Biosciences Inc
Top-line data from withdrawal study of INGREZZA
Pediatric patients with Tourette syndrome
after Q4 2019
Iterum Therapeutics plc
Filing of NDA for Oral Sulopenem
Uncomplicated urinary tract infections (uUTI), complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI)
Sep 2019
CHIASMA, INC
Top-line data from phase III clinical trial of octreotide capsules (CHIASMA OPTIMAL)
Acromegaly in adults
after Q4 2019
Arcus Biosciences, Inc
Initial data from the expansion cohorts for AB928 + AB122 and AB928 + chemotherapy combinations
Cancer
after Q4 2019
Acasti Pharma, Inc.
Top line results from two-trial phase III clinical program to evaluate safety and efficacy of CaPre
Severe hypertriglyceridemia
after Q4 2019
BioLineRx Ltd.
Results from additional cohort in Phase 2a COMBAT study of BL-8040, KEYTRUDA and chemotherapy
Pancreatic cancer
after Q4 2019
Unum Therapeutics Inc.
Preliminary data from phase I trial of ACTR T cells in combination with Trastuzumab (ATTCK-34-01)
HER2+ advanced cancers
after Q4 2019
Logic Devices Inc.
Filing of IND for LB-001
Methylmalonic academia
after Q4 2019
Alnylam Pharmaceuticals Inc.
Top-line results from phase III study of Lumasiran (ILLUMINATE-A)
Primary hyperoxaluria type 1 (PH1)
after Q4 2019
Marker Therapeutics, Inc
Interim data from phase II study of TPIV200
Ovarian cancer
after Q4 2019
Aurinia Pharmaceuticals Inc.
AUPH, AUP.V
Data from phase III trial of Voclosporin (AURORA)
Lupus nephritis
after Q4 2019
Unum Therapeutics Inc.
Data from phase I clinical trial of ACTR087 in combination with Rituxan (ATTCK-20-2)
Relapsed or refractory B cell non-Hodgkin lymphoma
after Q4 2019
VERU INC.
Results from phase Ib/II clinical trial of VERU-111
Metastatic refractory prostate cancer in Men
after Q4 2019
Cellular Biomedicine Group Inc.
Clinical data from ongoing B-cell maturation antigen (BCMA) study
Multiple Myeloma
after Q4 2019
Liquidia Technologies Inc.
Submission of NDA for LIQ861
Pulmonary arterial hypertension, or PAH
after Q4 2019
STEALTH BIOTHERAPEUTICS CORP
Top-line data from phase III clinical trial of Elamipretide
Primary mitochondrial myopathy
after Q4 2019
Wave Life Sciences Ltd.
Topline data readout from Phase 1b/2a clinical trial of WVE-120101 (PRECISION-HD)
Huntington's disease
after Q4 2019
Wave Life Sciences Ltd.
Topline data readout from Phase 1b/2a clinical trial of WVE-120102 (PRECISION-HD)
Huntington's disease
after Q4 2019
PIERIS PHARMACEUTICALS, INC.
Comprehensive data from phase I dose-escalation study of PRS-343
HER2-positive solid tumors
after Q4 2019
PIERIS PHARMACEUTICALS, INC.
Filing of IND for PRS-344
PD-L1/4-1BB bispecific drug candidate being co-developed with Servier